세계의 항생제 내성 시장 : 유형별, 작용기작별, 활성 스펙트럼별, 약제 클래스별, 투여 경로별, 최종 사용자별, 유통 채널별 예측(2025-2030년)

The Antibiotic Resistance Market was valued at USD 9.02 billion in 2023, expected to reach USD 9.87 billion in 2024, and is projected to grow at a CAGR of 9.40%, to USD 16.93 billion by 2030.

Antibiotic resistance, a critical public health issue, refers to the ability of bacteria and other microbes to resist the effects of drugs that once successfully treated infections. This resistance poses a significant threat globally, affecting both human and animal health, with substantial implications for agriculture, healthcare, and economic stability. The necessity for addressing antibiotic resistance lies in its potential to render common treatments ineffective, leading to prolonged illnesses and increased mortality. Applications are vast, including in healthcare, where new classes of antibiotics are urgently needed, and agriculture, where responsible usage is being driven by policy changes. The end-use sectors are largely healthcare providers, pharmaceutical companies, and regulatory bodies.

Market insights reveal key growth drivers such as the rising incidence of drug-resistant infections, governmental initiatives for prudent antibiotic use, and increased funding for R&D in alternative treatments like bacteriophages and antimicrobial peptides. The biotechnology industry's innovations, particularly in rapid diagnostic tools and personalized medicine, herald substantial opportunities. However, limitations such as the slow pace of new antibiotics development due to high costs and stringent regulations pose challenges. Additional factors affecting growth include the potential misuse of antibiotics in low-regulation markets and disparities in global access to new treatments.

Opportunities abound in enhancing rapid diagnostic technologies, which can minimize misuse and conserve antibiotic efficacy, and developing alternative therapies such as probiotics and vaccines. Recommendations for businesses include investing in collaborative R&D efforts and advocating for supportive policy frameworks to expedite drug approvals. Innovative research areas like harnessing CRISPR-based technologies for targeted antimicrobial therapies are particularly promising. The market is highly dynamic, driven by technological advancements and regulatory landscapes, presenting an urgent yet opportunistic field for stakeholders aiming to mitigate antibiotic resistance while capitalizing on emerging scientific breakthroughs.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Antibiotic Resistance Market

The Antibiotic Resistance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • High healthcare costs associated with antibiotic-resistant infections contributing to market growth
  • Growing adoption of rapid diagnostic tests for antibiotic resistance driving market demand
  • Increased collaboration between pharmaceutical companies and research institutions to address antibiotic resistance
  • Emerging markets showing significant interest and potential in antibiotic resistance solutions
• Market Restraints
  • Regulatory hurdles and approval delays hindering the introduction of novel antibiotics
• Market Opportunities
  • Development of novel antibiotics targeting antibiotic resistant bacterial strains to address critical healthcare needs
  • Implementation of advanced diagnostic tools for early detection and management of antibiotic resistant infections
  • Exploration of alternative therapies such as bacteriophages and probiotics to combat antibiotic resistance
• Market Challenges
  • Lack of collaboration between pharmaceutical companies and academic institutions in antibiotic research

Porter's Five Forces: A Strategic Tool for Navigating the Antibiotic Resistance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Antibiotic Resistance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Antibiotic Resistance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Antibiotic Resistance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Antibiotic Resistance Market

A detailed market share analysis in the Antibiotic Resistance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Antibiotic Resistance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Antibiotic Resistance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Antibiotic Resistance Market

A strategic analysis of the Antibiotic Resistance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Antibiotic Resistance Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan plc, Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Antibiotic Resistance Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Antibacterial Products, Antifungal Products, Antiparasitic Products, and Antiviral Products.
• Based on Mechanism of Action, market is studied across Cell Wall Synthesis Inhibitors, DNA Gyrase Inhibitors, Protein Synthesis Inhibitors, and RNA Polymerase Inhibitors.
• Based on Spectrum of Activity, market is studied across Broad-Spectrum Antibiotics and Narrow-Spectrum Antibiotics.
• Based on Drug Class, market is studied across Cephalosporins, Fluoroquinolones, Macrolides, Penicillins, and Tetracyclines.
• Based on Route of Administration, market is studied across Intravenous and Oral.
• Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. High healthcare costs associated with antibiotic-resistant infections contributing to market growth
    • 5.1.1.2. Growing adoption of rapid diagnostic tests for antibiotic resistance driving market demand
    • 5.1.1.3. Increased collaboration between pharmaceutical companies and research institutions to address antibiotic resistance
    • 5.1.1.4. Emerging markets showing significant interest and potential in antibiotic resistance solutions
  • 5.1.2. Restraints
    • 5.1.2.1. Regulatory hurdles and approval delays hindering the introduction of novel antibiotics
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of novel antibiotics targeting antibiotic resistant bacterial strains to address critical healthcare needs
    • 5.1.3.2. Implementation of advanced diagnostic tools for early detection and management of antibiotic resistant infections
    • 5.1.3.3. Exploration of alternative therapies such as bacteriophages and probiotics to combat antibiotic resistance
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of collaboration between pharmaceutical companies and academic institutions in antibiotic research
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antibiotic Resistance Market, by Type

• 6.1. Introduction
• 6.2. Antibacterial Products
• 6.3. Antifungal Products
• 6.4. Antiparasitic Products
• 6.5. Antiviral Products

7. Antibiotic Resistance Market, by Mechanism of Action

• 7.1. Introduction
• 7.2. Cell Wall Synthesis Inhibitors
• 7.3. DNA Gyrase Inhibitors
• 7.4. Protein Synthesis Inhibitors
• 7.5. RNA Polymerase Inhibitors

8. Antibiotic Resistance Market, by Spectrum of Activity

• 8.1. Introduction
• 8.2. Broad-Spectrum Antibiotics
• 8.3. Narrow-Spectrum Antibiotics

9. Antibiotic Resistance Market, by Drug Class

• 9.1. Introduction
• 9.2. Cephalosporins
• 9.3. Fluoroquinolones
• 9.4. Macrolides
• 9.5. Penicillins
• 9.6. Tetracyclines

10. Antibiotic Resistance Market, by Route of Administration

• 10.1. Introduction
• 10.2. Intravenous
• 10.3. Oral

11. Antibiotic Resistance Market, by End User

• 11.1. Introduction
• 11.2. Clinics
• 11.3. Homecare Settings
• 11.4. Hospitals

12. Antibiotic Resistance Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Hospital Pharmacies
• 12.3. Online Pharmacies
• 12.4. Retail Pharmacies

13. Americas Antibiotic Resistance Market

• 13.1. Introduction
• 13.2. Argentina
• 13.3. Brazil
• 13.4. Canada
• 13.5. Mexico
• 13.6. United States

14. Asia-Pacific Antibiotic Resistance Market

• 14.1. Introduction
• 14.2. Australia
• 14.3. China
• 14.4. India
• 14.5. Indonesia
• 14.6. Japan
• 14.7. Malaysia
• 14.8. Philippines
• 14.9. Singapore
• 14.10. South Korea
• 14.11. Taiwan
• 14.12. Thailand
• 14.13. Vietnam

15. Europe, Middle East & Africa Antibiotic Resistance Market

• 15.1. Introduction
• 15.2. Denmark
• 15.3. Egypt
• 15.4. Finland
• 15.5. France
• 15.6. Germany
• 15.7. Israel
• 15.8. Italy
• 15.9. Netherlands
• 15.10. Nigeria
• 15.11. Norway
• 15.12. Poland
• 15.13. Qatar
• 15.14. Russia
• 15.15. Saudi Arabia
• 15.16. South Africa
• 15.17. Spain
• 15.18. Sweden
• 15.19. Switzerland
• 15.20. Turkey
• 15.21. United Arab Emirates
• 15.22. United Kingdom

16. Competitive Landscape

• 16.1. Market Share Analysis, 2023
• 16.2. FPNV Positioning Matrix, 2023
• 16.3. Competitive Scenario Analysis
• 16.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Allergan plc
• 3. Amgen Inc.
• 4. AstraZeneca PLC
• 5. Aurobindo Pharma Limited
• 6. Bayer AG
• 7. Bristol-Myers Squibb Company
• 8. Cipla Limited
• 9. Eli Lilly and Company
• 10. Gilead Sciences, Inc.
• 11. GlaxoSmithKline plc
• 12. Johnson & Johnson
• 13. Merck & Co., Inc.
• 14. Novartis AG
• 15. Pfizer Inc.
• 16. Roche Holding AG
• 17. Sanofi S.A.
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Teva Pharmaceutical Industries Ltd.